[
    {
        "id": 9987,
        "drug_name": "KEYTRUDA (pembrolizumab) combined with chemotherapy",
        "clinical_trial_id": "NCT03675737",
        "has_trial_insight_page": 0,
        "indication": "Advanced unresectable or metastatic gastric (GEJ) adenocarcinoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-11-17",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/MRK\/news\/170745",
        "note": "Approved November 17, 2023.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9882,
        "drug_name": "Truqap (capivasertib) plus Faslodex",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "HR-positive breast cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-11-17",
        "link": "https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/truqap-approved-in-us-for-hr-plus-breast-cancer.html",
        "note": "Approved November 17, 2023.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": [
            {
                "label": "Fast Track Designation (FTD)",
                "abbreviation": "FTD",
                "description": "Fast Track Designation (FTD)",
                "description_html": "<p>Fast Track Designation (FTD)<\/p>\n"
            }
        ]
    },
    {
        "id": 10861,
        "drug_name": "Forteo (teriparatide injection)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Osteoporosis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-11-17",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/TEVA\/news\/170808",
        "note": "FDA approval of biosimilar generic drug, noted November 17, 2023.",
        "company_entity_id": 390,
        "company_ticker": "TEVA",
        "company_name": "Teva Pharmaceutical Industries Limited American Depositary Shares",
        "company_price": "13.4900",
        "company_change": 0.14,
        "company_percent_change": 1.05,
        "company_optionable": 1,
        "company_number_of_shares": 1121094011,
        "price_change_sparkline": [
            [
                12.1,
                1706677200
            ],
            [
                12.46,
                1706763600
            ],
            [
                12.28,
                1706850000
            ],
            [
                12.38,
                1707109200
            ],
            [
                12.25,
                1707195600
            ],
            [
                12.14,
                1707282000
            ],
            [
                12.09,
                1707368400
            ],
            [
                12.01,
                1707454800
            ],
            [
                12.91,
                1707714000
            ],
            [
                12.92,
                1707800400
            ],
            [
                13.17,
                1707886800
            ],
            [
                13.2,
                1707973200
            ],
            [
                13.02,
                1708059600
            ],
            [
                13.07,
                1708405200
            ],
            [
                13,
                1708491600
            ],
            [
                13.05,
                1708578000
            ],
            [
                12.89,
                1708664400
            ],
            [
                13.29,
                1708923600
            ],
            [
                13.3,
                1709010000
            ],
            [
                13.09,
                1709096400
            ],
            [
                13.15,
                1709182800
            ],
            [
                13.5,
                1709269200
            ],
            [
                13.44,
                1709528400
            ],
            [
                13.54,
                1709614800
            ],
            [
                13.53,
                1709701200
            ],
            [
                13.71,
                1709787600
            ],
            [
                13.62,
                1709874000
            ],
            [
                13.35,
                1710129600
            ],
            [
                13.49,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6071,
        "drug_name": "OGSIVEO (Nirogacestat) - (DeFi)",
        "clinical_trial_id": "NCT03785964",
        "has_trial_insight_page": 1,
        "indication": "Desmoid tumors",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-11-27",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/SWTX\/news\/172018",
        "note": "FDA Approved on November 27, 2023.",
        "company_entity_id": 701,
        "company_ticker": "SWTX",
        "company_name": "SpringWorks Therapeutics Inc.",
        "company_price": "49.7500",
        "company_change": 1.31,
        "company_percent_change": 2.7,
        "company_optionable": 1,
        "company_number_of_shares": 73786845,
        "price_change_sparkline": [
            [
                44.13,
                1706677200
            ],
            [
                44.53,
                1706763600
            ],
            [
                46.155,
                1706850000
            ],
            [
                48.08,
                1707109200
            ],
            [
                49.07,
                1707195600
            ],
            [
                44.75,
                1707282000
            ],
            [
                46.43,
                1707368400
            ],
            [
                46.96,
                1707454800
            ],
            [
                45.91,
                1707714000
            ],
            [
                44.7,
                1707800400
            ],
            [
                46.53,
                1707886800
            ],
            [
                48.03,
                1707973200
            ],
            [
                52.38,
                1708059600
            ],
            [
                48.82,
                1708405200
            ],
            [
                49.22,
                1708491600
            ],
            [
                49.11,
                1708578000
            ],
            [
                49.12,
                1708664400
            ],
            [
                48.48,
                1708923600
            ],
            [
                52.07,
                1709010000
            ],
            [
                48.61,
                1709096400
            ],
            [
                49.26,
                1709182800
            ],
            [
                51.01,
                1709269200
            ],
            [
                49.75,
                1709528400
            ],
            [
                50.34,
                1709614800
            ],
            [
                52.42,
                1709701200
            ],
            [
                52.5,
                1709787600
            ],
            [
                51.07,
                1709874000
            ],
            [
                48.44,
                1710129600
            ],
            [
                49.75,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10042,
        "drug_name": "Fabhalta (iptacopan)",
        "clinical_trial_id": "NCT04558918",
        "has_trial_insight_page": 0,
        "indication": "Paroxysmal nocturnal hemoglobinuria (PNH)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-12-06",
        "link": "https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-fda-approval-fabhalta-iptacopan-offering-superior-hemoglobin-improvement-absence-transfusions-first-oral-monotherapy-adults-pnh",
        "note": "Approved December 6, 2023.",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7741,
        "drug_name": "Beyfortus (Nirsevimab) - (MEDLEY)",
        "clinical_trial_id": "NCT03959488",
        "has_trial_insight_page": 1,
        "indication": "Respiratory Syncytial Virus",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-12-06",
        "link": "https:\/\/www.sanofi.com\/assets\/dotcom\/content-app\/events\/investor-presentation\/2023\/r-and-d-day-2023\/Presentation.pdf",
        "note": "Approved, noted December 6, 2023.",
        "company_entity_id": 389,
        "company_ticker": "SNY",
        "company_name": "Sanofi",
        "company_price": "48.4600",
        "company_change": 0.11,
        "company_percent_change": 0.23,
        "company_optionable": 1,
        "company_number_of_shares": 2529599938,
        "price_change_sparkline": [
            [
                49.9,
                1706677200
            ],
            [
                48.41,
                1706763600
            ],
            [
                47.23,
                1706850000
            ],
            [
                46.95,
                1707109200
            ],
            [
                47.06,
                1707195600
            ],
            [
                46.92,
                1707282000
            ],
            [
                46.56,
                1707368400
            ],
            [
                46.5,
                1707454800
            ],
            [
                46.34,
                1707714000
            ],
            [
                45.75,
                1707800400
            ],
            [
                45.8,
                1707886800
            ],
            [
                46.39,
                1707973200
            ],
            [
                46.18,
                1708059600
            ],
            [
                46.85,
                1708405200
            ],
            [
                47.92,
                1708491600
            ],
            [
                47.8,
                1708578000
            ],
            [
                48.77,
                1708664400
            ],
            [
                48.2,
                1708923600
            ],
            [
                48.21,
                1709010000
            ],
            [
                48,
                1709096400
            ],
            [
                47.85,
                1709182800
            ],
            [
                47.29,
                1709269200
            ],
            [
                47.15,
                1709528400
            ],
            [
                47.5,
                1709614800
            ],
            [
                47.68,
                1709701200
            ],
            [
                48.06,
                1709787600
            ],
            [
                48.25,
                1709874000
            ],
            [
                48.35,
                1710129600
            ],
            [
                48.46,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 11292,
        "drug_name": "CRESEMBA (isavuconazonium sulfate)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Invasive Aspergillosis and Invasive Mucormycosis in Children",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-12-08",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/ALPMY\/news\/191095",
        "note": "Approved December 8, 2023.",
        "company_entity_id": 2240,
        "company_ticker": "ALPMY",
        "company_name": "Astellas Pharma Inc. ADR",
        "company_price": "10.7600",
        "company_change": -0.13,
        "company_percent_change": -1.19,
        "company_optionable": 0,
        "company_number_of_shares": 1808873137,
        "price_change_sparkline": [
            [
                11.6,
                1706677200
            ],
            [
                11.55,
                1706763600
            ],
            [
                11.35,
                1706850000
            ],
            [
                11,
                1707109200
            ],
            [
                10.89,
                1707195600
            ],
            [
                10.92,
                1707282000
            ],
            [
                10.73,
                1707368400
            ],
            [
                10.79,
                1707454800
            ],
            [
                10.82,
                1707714000
            ],
            [
                10.89,
                1707800400
            ],
            [
                11.075,
                1707886800
            ],
            [
                11.05,
                1707973200
            ],
            [
                11.1,
                1708059600
            ],
            [
                11.14,
                1708405200
            ],
            [
                11.12,
                1708491600
            ],
            [
                10.96,
                1708578000
            ],
            [
                10.99,
                1708664400
            ],
            [
                11.03,
                1708923600
            ],
            [
                10.99,
                1709010000
            ],
            [
                10.98,
                1709096400
            ],
            [
                10.93,
                1709182800
            ],
            [
                11.15,
                1709269200
            ],
            [
                11.08,
                1709528400
            ],
            [
                10.8,
                1709614800
            ],
            [
                10.81,
                1709701200
            ],
            [
                10.75,
                1709787600
            ],
            [
                10.62,
                1709874000
            ],
            [
                10.89,
                1710129600
            ],
            [
                10.76,
                1710216000
            ]
        ],
        "statuses": [
            {
                "label": "Orphan Drug Designation (ODD)",
                "abbreviation": "ODD",
                "description": "Orphan Drug Designation (ODD)",
                "description_html": "<p>Orphan Drug Designation (ODD)<\/p>\n"
            }
        ]
    },
    {
        "id": 4741,
        "drug_name": "Casgevy (Exagamglogene autotemcel (exa-cel))",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Sickle cell disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-12-08",
        "link": "https:\/\/www.statnews.com\/2023\/12\/08\/fda-approves-casgevy-crispr-based-medicine-for-treatment-of-sickle-cell-disease\/?utm_campaign=breaking_news&utm_medium=email&_hsmi=285761583&_hsenc=p2ANqtz--44VxqO_8gPBayRbtEFZqn_HP52sZDj7C5-dHs3lqFYfm5bje0rwbFDDWXLkVxNwRJyNGRlq8-7In_C0rnMBw_kBhrHA&utm_content=285761583&utm_source=hs_email",
        "note": "Approved December 8, 2023",
        "company_entity_id": 544,
        "company_ticker": "CRSP",
        "company_name": "CRISPR Therapeutics AG",
        "company_price": "75.3000",
        "company_change": -1.52,
        "company_percent_change": -1.98,
        "company_optionable": 1,
        "company_number_of_shares": 80275950,
        "price_change_sparkline": [
            [
                62.95,
                1706677200
            ],
            [
                64.67,
                1706763600
            ],
            [
                64.75,
                1706850000
            ],
            [
                64.51,
                1707109200
            ],
            [
                66.88,
                1707195600
            ],
            [
                65.72,
                1707282000
            ],
            [
                68.83,
                1707368400
            ],
            [
                70.01,
                1707454800
            ],
            [
                76.44,
                1707714000
            ],
            [
                72.78,
                1707800400
            ],
            [
                79.04,
                1707886800
            ],
            [
                84.48,
                1707973200
            ],
            [
                82.22,
                1708059600
            ],
            [
                78.73,
                1708405200
            ],
            [
                82.41,
                1708491600
            ],
            [
                86.19,
                1708578000
            ],
            [
                83.99,
                1708664400
            ],
            [
                86.06,
                1708923600
            ],
            [
                89.12,
                1709010000
            ],
            [
                87.68,
                1709096400
            ],
            [
                84.22,
                1709182800
            ],
            [
                83.75,
                1709269200
            ],
            [
                81.74,
                1709528400
            ],
            [
                80.99,
                1709614800
            ],
            [
                80.83,
                1709701200
            ],
            [
                79.37,
                1709787600
            ],
            [
                78.92,
                1709874000
            ],
            [
                76.82,
                1710129600
            ],
            [
                75.3,
                1710216000
            ]
        ],
        "statuses": [
            {
                "label": "Fast Track Designation (FTD)",
                "abbreviation": "FTD",
                "description": "Fast Track Designation (FTD)",
                "description_html": "<p>Fast Track Designation (FTD)<\/p>\n"
            },
            {
                "label": "Orphan Drug Designation (ODD)",
                "abbreviation": "ODD",
                "description": "Orphan Drug Designation (ODD)",
                "description_html": "<p>Orphan Drug Designation (ODD)<\/p>\n"
            }
        ]
    },
    {
        "id": 4741,
        "drug_name": "Casgevy (Exagamglogene autotemcel (exa-cel))",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Sickle cell disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-12-08",
        "link": "https:\/\/www.statnews.com\/2023\/12\/08\/fda-approves-casgevy-crispr-based-medicine-for-treatment-of-sickle-cell-disease\/?utm_campaign=breaking_news&utm_medium=email&_hsmi=285761583&_hsenc=p2ANqtz--44VxqO_8gPBayRbtEFZqn_HP52sZDj7C5-dHs3lqFYfm5bje0rwbFDDWXLkVxNwRJyNGRlq8-7In_C0rnMBw_kBhrHA&utm_content=285761583&utm_source=hs_email",
        "note": "Approved December 8, 2023",
        "company_entity_id": 306,
        "company_ticker": "VRTX",
        "company_name": "Vertex Pharmaceuticals Incorporated",
        "company_price": "412.4500",
        "company_change": -2.02,
        "company_percent_change": -0.49,
        "company_optionable": 1,
        "company_number_of_shares": 258307816,
        "price_change_sparkline": [
            [
                433.38,
                1706677200
            ],
            [
                433.87,
                1706763600
            ],
            [
                424.68,
                1706850000
            ],
            [
                428.89,
                1707109200
            ],
            [
                416.13,
                1707195600
            ],
            [
                419.08,
                1707282000
            ],
            [
                423.06,
                1707368400
            ],
            [
                422.91,
                1707454800
            ],
            [
                418.53,
                1707714000
            ],
            [
                416.04,
                1707800400
            ],
            [
                417.88,
                1707886800
            ],
            [
                426.29,
                1707973200
            ],
            [
                422.2,
                1708059600
            ],
            [
                420.64,
                1708405200
            ],
            [
                419.63,
                1708491600
            ],
            [
                426.78,
                1708578000
            ],
            [
                430.11,
                1708664400
            ],
            [
                433.48,
                1708923600
            ],
            [
                430.92,
                1709010000
            ],
            [
                426.97,
                1709096400
            ],
            [
                420.74,
                1709182800
            ],
            [
                432.76,
                1709269200
            ],
            [
                424.03,
                1709528400
            ],
            [
                415.44,
                1709614800
            ],
            [
                411.85,
                1709701200
            ],
            [
                410.54,
                1709787600
            ],
            [
                413.59,
                1709874000
            ],
            [
                414.47,
                1710129600
            ],
            [
                412.45,
                1710216000
            ]
        ],
        "statuses": [
            {
                "label": "Fast Track Designation (FTD)",
                "abbreviation": "FTD",
                "description": "Fast Track Designation (FTD)",
                "description_html": "<p>Fast Track Designation (FTD)<\/p>\n"
            },
            {
                "label": "Orphan Drug Designation (ODD)",
                "abbreviation": "ODD",
                "description": "Orphan Drug Designation (ODD)",
                "description_html": "<p>Orphan Drug Designation (ODD)<\/p>\n"
            }
        ]
    },
    {
        "id": 3409,
        "drug_name": "LYFGENIA (lovotibeglogene autotemcel)",
        "clinical_trial_id": "NCT02140554",
        "has_trial_insight_page": 0,
        "indication": "Sickle cell disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-12-08",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/BLUE\/news\/174284",
        "note": "Approved December 8, 2023.",
        "company_entity_id": 68,
        "company_ticker": "BLUE",
        "company_name": "bluebird bio Inc.",
        "company_price": "1.3450",
        "company_change": -0.050000000000000044,
        "company_percent_change": -3.24,
        "company_optionable": 1,
        "company_number_of_shares": 109336211,
        "price_change_sparkline": [
            [
                1.02,
                1706677200
            ],
            [
                0.9987,
                1706763600
            ],
            [
                0.9561,
                1706850000
            ],
            [
                0.9052,
                1707109200
            ],
            [
                0.94,
                1707195600
            ],
            [
                0.9357,
                1707282000
            ],
            [
                1.05,
                1707368400
            ],
            [
                1.03,
                1707454800
            ],
            [
                1.09,
                1707714000
            ],
            [
                0.9826,
                1707800400
            ],
            [
                1.025,
                1707886800
            ],
            [
                1.08,
                1707973200
            ],
            [
                1.02,
                1708059600
            ],
            [
                1.1,
                1708405200
            ],
            [
                1.09,
                1708491600
            ],
            [
                1.18,
                1708578000
            ],
            [
                1.25,
                1708664400
            ],
            [
                1.46,
                1708923600
            ],
            [
                1.75,
                1709010000
            ],
            [
                1.68,
                1709096400
            ],
            [
                1.39,
                1709182800
            ],
            [
                1.565,
                1709269200
            ],
            [
                1.53,
                1709528400
            ],
            [
                1.39,
                1709614800
            ],
            [
                1.45,
                1709701200
            ],
            [
                1.45,
                1709787600
            ],
            [
                1.5,
                1709874000
            ],
            [
                1.39,
                1710129600
            ],
            [
                1.345,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2410,
        "drug_name": "Cytisine - (ORCA-2)",
        "clinical_trial_id": "NCT04576949",
        "has_trial_insight_page": 1,
        "indication": "Smoking cessation",
        "label": "NDA Filing",
        "value": "ndaFiling",
        "simplified_stage": "phase4",
        "stageid": 10,
        "stage_name": "NDA Filing",
        "date": "2023-12-12",
        "link": "https:\/\/ir.achievelifesciences.com\/sec-filings\/all-sec-filings\/content\/0000950170-23-069392\/0000950170-23-069392.pdf",
        "note": "Phase 3 conducted a pre-New Drug Application (NDA) meeting with the FDA. During that meeting, the FDA expressed support for an NDA submission based on adequate data to assess efficacy from the two\r\nrandomized and controlled Phase 3 trials. In addition, the FDA advised that long-term exposure data beyond 12 weeks would be needed. Following receipt of additional input from the FDA, anticipated in the 1Q 2024, the Company will provide an update on its projected NDA submission timing, noted December 12, 2023.",
        "company_entity_id": 438,
        "company_ticker": "ACHV",
        "company_name": "Achieve Life Sciences Inc.",
        "company_price": "4.3500",
        "company_change": 0,
        "company_percent_change": 0,
        "company_optionable": 1,
        "company_number_of_shares": 21165760,
        "price_change_sparkline": [
            [
                4.93,
                1706677200
            ],
            [
                5,
                1706763600
            ],
            [
                4.85,
                1706850000
            ],
            [
                4.35,
                1707109200
            ],
            [
                4.5,
                1707195600
            ],
            [
                4.39,
                1707282000
            ],
            [
                4.37,
                1707368400
            ],
            [
                4.5,
                1707454800
            ],
            [
                4.67,
                1707714000
            ],
            [
                4.47,
                1707800400
            ],
            [
                4.39,
                1707886800
            ],
            [
                4.43,
                1707973200
            ],
            [
                4.32,
                1708059600
            ],
            [
                4.01,
                1708405200
            ],
            [
                4,
                1708491600
            ],
            [
                3.82,
                1708578000
            ],
            [
                3.96,
                1708664400
            ],
            [
                4.09,
                1708923600
            ],
            [
                4.5,
                1709010000
            ],
            [
                4.46,
                1709096400
            ],
            [
                4.05,
                1709182800
            ],
            [
                4.42,
                1709269200
            ],
            [
                4.42,
                1709528400
            ],
            [
                4.39,
                1709614800
            ],
            [
                4.43,
                1709701200
            ],
            [
                4.38,
                1709787600
            ],
            [
                4.39,
                1709874000
            ],
            [
                4.35,
                1710129600
            ],
            [
                4.35,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10954,
        "drug_name": "NEXLETOL\/NEXLIZET",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Primary hyperlipidemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-12-13",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/ESPR\/news\/175214",
        "note": "Approved December 13, 2023.",
        "company_entity_id": 133,
        "company_ticker": "ESPR",
        "company_name": "Esperion Therapeutics Inc.",
        "company_price": "2.0500",
        "company_change": -0.06999999999999995,
        "company_percent_change": -3.3,
        "company_optionable": 1,
        "company_number_of_shares": 185052705,
        "price_change_sparkline": [
            [
                2.14,
                1706677200
            ],
            [
                2.07,
                1706763600
            ],
            [
                2.19,
                1706850000
            ],
            [
                2.38,
                1707109200
            ],
            [
                2.58,
                1707195600
            ],
            [
                2.63,
                1707282000
            ],
            [
                2.58,
                1707368400
            ],
            [
                2.58,
                1707454800
            ],
            [
                2.6,
                1707714000
            ],
            [
                2.54,
                1707800400
            ],
            [
                2.61,
                1707886800
            ],
            [
                2.66,
                1707973200
            ],
            [
                2.69,
                1708059600
            ],
            [
                2.68,
                1708405200
            ],
            [
                2.61,
                1708491600
            ],
            [
                2.63,
                1708578000
            ],
            [
                2.61,
                1708664400
            ],
            [
                2.63,
                1708923600
            ],
            [
                2.9,
                1709010000
            ],
            [
                2.57,
                1709096400
            ],
            [
                2.51,
                1709182800
            ],
            [
                2.55,
                1709269200
            ],
            [
                2.44,
                1709528400
            ],
            [
                2.4,
                1709614800
            ],
            [
                2.46,
                1709701200
            ],
            [
                2.28,
                1709787600
            ],
            [
                2.19,
                1709874000
            ],
            [
                2.12,
                1710129600
            ],
            [
                2.05,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6455,
        "drug_name": "iDose TR",
        "clinical_trial_id": "NCT03519386",
        "has_trial_insight_page": 1,
        "indication": "Glaucoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-12-14",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/GKOS\/news\/175308",
        "note": "FDA Approval on December 14, 2023.",
        "company_entity_id": 725,
        "company_ticker": "GKOS",
        "company_name": "Glaukos Corporation",
        "company_price": "87.0000",
        "company_change": 0.14,
        "company_percent_change": 0.16,
        "company_optionable": 1,
        "company_number_of_shares": 49470423,
        "price_change_sparkline": [
            [
                89.03,
                1706677200
            ],
            [
                91.87,
                1706763600
            ],
            [
                91.94,
                1706850000
            ],
            [
                91.08,
                1707109200
            ],
            [
                93.31,
                1707195600
            ],
            [
                94.3,
                1707282000
            ],
            [
                95.99,
                1707368400
            ],
            [
                96.25,
                1707454800
            ],
            [
                96.33,
                1707714000
            ],
            [
                93.57,
                1707800400
            ],
            [
                94.73,
                1707886800
            ],
            [
                96.11,
                1707973200
            ],
            [
                92.63,
                1708059600
            ],
            [
                92.13,
                1708405200
            ],
            [
                92.79,
                1708491600
            ],
            [
                91.46,
                1708578000
            ],
            [
                89.57,
                1708664400
            ],
            [
                91.63,
                1708923600
            ],
            [
                90.47,
                1709010000
            ],
            [
                90.04,
                1709096400
            ],
            [
                88.59,
                1709182800
            ],
            [
                88.82,
                1709269200
            ],
            [
                88.56,
                1709528400
            ],
            [
                84.31,
                1709614800
            ],
            [
                85.5,
                1709701200
            ],
            [
                88.91,
                1709787600
            ],
            [
                87.46,
                1709874000
            ],
            [
                86.86,
                1710129600
            ],
            [
                87,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10720,
        "drug_name": "WELIREG (belzutifan)",
        "clinical_trial_id": "NCT04195750",
        "has_trial_insight_page": 0,
        "indication": "Advanced Renal Cell Carcinoma (RCC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-12-14",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/MRK\/news\/175544",
        "note": "Approved December 14, 2023.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10699,
        "drug_name": "PADCEV (enfortumab vedotin-ejfv) in combination with KEYTRUDA (pembrolizumab) versus chemotherapy - (EV-302 \/KEYNOTE-A39)",
        "clinical_trial_id": "NCT04223856",
        "has_trial_insight_page": 0,
        "indication": "Untreated locally advanced or metastatic urothelial cancer (la\/mUC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-12-15",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/PFE\/news\/175662",
        "note": "FDA Approval on December 15, 2023.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10699,
        "drug_name": "PADCEV (enfortumab vedotin-ejfv) in combination with KEYTRUDA (pembrolizumab) versus chemotherapy - (EV-302 \/KEYNOTE-A39)",
        "clinical_trial_id": "NCT04223856",
        "has_trial_insight_page": 0,
        "indication": "Untreated locally advanced or metastatic urothelial cancer (la\/mUC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-12-15",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/PFE\/news\/175662",
        "note": "FDA Approval on December 15, 2023.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10699,
        "drug_name": "PADCEV (enfortumab vedotin-ejfv) in combination with KEYTRUDA (pembrolizumab) versus chemotherapy - (EV-302 \/KEYNOTE-A39)",
        "clinical_trial_id": "NCT04223856",
        "has_trial_insight_page": 0,
        "indication": "Untreated locally advanced or metastatic urothelial cancer (la\/mUC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-12-15",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/PFE\/news\/175662",
        "note": "FDA Approval on December 15, 2023.",
        "company_entity_id": 2240,
        "company_ticker": "ALPMY",
        "company_name": "Astellas Pharma Inc. ADR",
        "company_price": "10.7600",
        "company_change": -0.13,
        "company_percent_change": -1.19,
        "company_optionable": 0,
        "company_number_of_shares": 1808873137,
        "price_change_sparkline": [
            [
                11.6,
                1706677200
            ],
            [
                11.55,
                1706763600
            ],
            [
                11.35,
                1706850000
            ],
            [
                11,
                1707109200
            ],
            [
                10.89,
                1707195600
            ],
            [
                10.92,
                1707282000
            ],
            [
                10.73,
                1707368400
            ],
            [
                10.79,
                1707454800
            ],
            [
                10.82,
                1707714000
            ],
            [
                10.89,
                1707800400
            ],
            [
                11.075,
                1707886800
            ],
            [
                11.05,
                1707973200
            ],
            [
                11.1,
                1708059600
            ],
            [
                11.14,
                1708405200
            ],
            [
                11.12,
                1708491600
            ],
            [
                10.96,
                1708578000
            ],
            [
                10.99,
                1708664400
            ],
            [
                11.03,
                1708923600
            ],
            [
                10.99,
                1709010000
            ],
            [
                10.98,
                1709096400
            ],
            [
                10.93,
                1709182800
            ],
            [
                11.15,
                1709269200
            ],
            [
                11.08,
                1709528400
            ],
            [
                10.8,
                1709614800
            ],
            [
                10.81,
                1709701200
            ],
            [
                10.75,
                1709787600
            ],
            [
                10.62,
                1709874000
            ],
            [
                10.89,
                1710129600
            ],
            [
                10.76,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6373,
        "drug_name": "ZORYVE (roflumilast)",
        "clinical_trial_id": "NCT04973228",
        "has_trial_insight_page": 1,
        "indication": "Seborrheic dermatitis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-12-15",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/ARQT\/news\/175665",
        "note": "Approved December 15, 2023.",
        "company_entity_id": 738,
        "company_ticker": "ARQT",
        "company_name": "Arcutis Biotherapeutics Inc.",
        "company_price": "10.1100",
        "company_change": 0.07,
        "company_percent_change": 0.7,
        "company_optionable": 1,
        "company_number_of_shares": 96813363,
        "price_change_sparkline": [
            [
                5.87,
                1706677200
            ],
            [
                6.64,
                1706763600
            ],
            [
                6.07,
                1706850000
            ],
            [
                6.02,
                1707109200
            ],
            [
                5.7,
                1707195600
            ],
            [
                5.71,
                1707282000
            ],
            [
                5.7,
                1707368400
            ],
            [
                6.57,
                1707454800
            ],
            [
                6.69,
                1707714000
            ],
            [
                6.9,
                1707800400
            ],
            [
                7.58,
                1707886800
            ],
            [
                7.97,
                1707973200
            ],
            [
                9.3,
                1708059600
            ],
            [
                9.48,
                1708405200
            ],
            [
                9.27,
                1708491600
            ],
            [
                9.62,
                1708578000
            ],
            [
                9.68,
                1708664400
            ],
            [
                9.69,
                1708923600
            ],
            [
                10.63,
                1709010000
            ],
            [
                10.41,
                1709096400
            ],
            [
                10.28,
                1709182800
            ],
            [
                11.77,
                1709269200
            ],
            [
                10.95,
                1709528400
            ],
            [
                10.9,
                1709614800
            ],
            [
                10.44,
                1709701200
            ],
            [
                10.38,
                1709787600
            ],
            [
                11.15,
                1709874000
            ],
            [
                10.04,
                1710129600
            ],
            [
                10.11,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10969,
        "drug_name": "Eflornithine",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "High-risk neuroblastoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-12-18",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/PBLA\/news\/175843",
        "note": "NDA approved by FDA December 18, 2023.",
        "company_entity_id": 862,
        "company_ticker": "PBLA",
        "company_name": "Panbela Therapeutics Inc.",
        "company_price": "0.6700",
        "company_change": -0.07999999999999996,
        "company_percent_change": -10.67,
        "company_optionable": 0,
        "company_number_of_shares": 480404,
        "price_change_sparkline": [
            [
                1.39,
                1706677200
            ],
            [
                1.26,
                1706763600
            ],
            [
                1.17,
                1706850000
            ],
            [
                1.16,
                1707109200
            ],
            [
                1.2,
                1707195600
            ],
            [
                1.16,
                1707282000
            ],
            [
                1.14,
                1707368400
            ],
            [
                1.24,
                1707454800
            ],
            [
                1.17,
                1707714000
            ],
            [
                1.13,
                1707800400
            ],
            [
                1.36,
                1707886800
            ],
            [
                1.27,
                1707973200
            ],
            [
                1.25,
                1708059600
            ],
            [
                1.18,
                1708405200
            ],
            [
                1.15,
                1708491600
            ],
            [
                1.11,
                1708578000
            ],
            [
                1.12,
                1708664400
            ],
            [
                1.15,
                1708923600
            ],
            [
                1.23,
                1709010000
            ],
            [
                1.19,
                1709096400
            ],
            [
                1.18,
                1709182800
            ],
            [
                1.27,
                1709269200
            ],
            [
                1.22,
                1709528400
            ],
            [
                1.23,
                1709614800
            ],
            [
                1.11,
                1709701200
            ],
            [
                0.6899,
                1709787600
            ],
            [
                0.555,
                1709874000
            ],
            [
                0.75,
                1710129600
            ],
            [
                0.67,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10245,
        "drug_name": "TARPEYO (budesonide)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "IgA Nephropathy",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-12-20",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/CALT\/news\/176517",
        "note": "Approved December 20, 2023.",
        "company_entity_id": 768,
        "company_ticker": "CALT",
        "company_name": "Calliditas Therapeutics AB",
        "company_price": "22.0700",
        "company_change": -0.18000000000000005,
        "company_percent_change": -0.81,
        "company_optionable": 1,
        "company_number_of_shares": 29786294,
        "price_change_sparkline": [
            [
                22.1801,
                1706677200
            ],
            [
                21.7286,
                1706763600
            ],
            [
                20.85,
                1706850000
            ],
            [
                20.75,
                1707109200
            ],
            [
                21.5099,
                1707195600
            ],
            [
                21.57,
                1707282000
            ],
            [
                21.5,
                1707368400
            ],
            [
                21.14,
                1707454800
            ],
            [
                21.4,
                1707714000
            ],
            [
                21.05,
                1707800400
            ],
            [
                20.67,
                1707886800
            ],
            [
                20.58,
                1707973200
            ],
            [
                21.24,
                1708059600
            ],
            [
                20.92,
                1708405200
            ],
            [
                20.3,
                1708491600
            ],
            [
                20.5,
                1708578000
            ],
            [
                20.04,
                1708664400
            ],
            [
                20.715,
                1708923600
            ],
            [
                22.07,
                1709010000
            ],
            [
                21.88,
                1709096400
            ],
            [
                21.3195,
                1709182800
            ],
            [
                21.43,
                1709269200
            ],
            [
                21.1,
                1709528400
            ],
            [
                20.455,
                1709614800
            ],
            [
                22.19,
                1709701200
            ],
            [
                23.13,
                1709787600
            ],
            [
                22.1,
                1709874000
            ],
            [
                22.25,
                1710129600
            ],
            [
                22.07,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5541,
        "drug_name": "WAINUA (eplontersen)",
        "clinical_trial_id": "NCT04136184",
        "has_trial_insight_page": 1,
        "indication": "ATTR Amyloidosis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-12-22",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/AZN\/news\/176762",
        "note": "Approved December 22, 2023.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5541,
        "drug_name": "WAINUA (eplontersen)",
        "clinical_trial_id": "NCT04136184",
        "has_trial_insight_page": 1,
        "indication": "ATTR Amyloidosis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-12-22",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/AZN\/news\/176762",
        "note": "Approved December 22, 2023.",
        "company_entity_id": 173,
        "company_ticker": "IONS",
        "company_name": "Ionis Pharmaceuticals Inc.",
        "company_price": "43.1700",
        "company_change": -0.08999999999999997,
        "company_percent_change": -0.20999999999999996,
        "company_optionable": 1,
        "company_number_of_shares": 145751797,
        "price_change_sparkline": [
            [
                51.39,
                1706677200
            ],
            [
                50.97,
                1706763600
            ],
            [
                49.75,
                1706850000
            ],
            [
                49.43,
                1707109200
            ],
            [
                49.12,
                1707195600
            ],
            [
                49.54,
                1707282000
            ],
            [
                49.98,
                1707368400
            ],
            [
                51.4,
                1707454800
            ],
            [
                50.38,
                1707714000
            ],
            [
                48.61,
                1707800400
            ],
            [
                49.07,
                1707886800
            ],
            [
                45.28,
                1707973200
            ],
            [
                44.43,
                1708059600
            ],
            [
                44.35,
                1708405200
            ],
            [
                43.53,
                1708491600
            ],
            [
                43.98,
                1708578000
            ],
            [
                45.36,
                1708664400
            ],
            [
                46.1,
                1708923600
            ],
            [
                47.41,
                1709010000
            ],
            [
                46.54,
                1709096400
            ],
            [
                45.21,
                1709182800
            ],
            [
                45.46,
                1709269200
            ],
            [
                44.87,
                1709528400
            ],
            [
                44.19,
                1709614800
            ],
            [
                44.29,
                1709701200
            ],
            [
                44.67,
                1709787600
            ],
            [
                43.99,
                1709874000
            ],
            [
                43.26,
                1710129600
            ],
            [
                43.17,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5229,
        "drug_name": "BRUKINSA (zanubrutinib)",
        "clinical_trial_id": "NCT03734016",
        "has_trial_insight_page": 0,
        "indication": "Refractory chronic lymphocytic leukemia (CLL)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-12-22",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/BGNE\/news\/176768",
        "note": "Approved December 22, 2023.",
        "company_entity_id": 340,
        "company_ticker": "BGNE",
        "company_name": "BeiGene Ltd.",
        "company_price": "163.7500",
        "company_change": -0.78,
        "company_percent_change": -0.47,
        "company_optionable": 1,
        "company_number_of_shares": 104577940,
        "price_change_sparkline": [
            [
                148.23,
                1706677200
            ],
            [
                149.93,
                1706763600
            ],
            [
                144.48,
                1706850000
            ],
            [
                141.81,
                1707109200
            ],
            [
                153.58,
                1707195600
            ],
            [
                147.76,
                1707282000
            ],
            [
                142.88,
                1707368400
            ],
            [
                146.98,
                1707454800
            ],
            [
                146.57,
                1707714000
            ],
            [
                141.8,
                1707800400
            ],
            [
                145.87,
                1707886800
            ],
            [
                146.07,
                1707973200
            ],
            [
                148.23,
                1708059600
            ],
            [
                148.05,
                1708405200
            ],
            [
                150.8,
                1708491600
            ],
            [
                153.78,
                1708578000
            ],
            [
                155.1,
                1708664400
            ],
            [
                160.26,
                1708923600
            ],
            [
                179.69,
                1709010000
            ],
            [
                178.48,
                1709096400
            ],
            [
                165.65,
                1709182800
            ],
            [
                165.02,
                1709269200
            ],
            [
                167.86,
                1709528400
            ],
            [
                160.42,
                1709614800
            ],
            [
                159.52,
                1709701200
            ],
            [
                162.25,
                1709787600
            ],
            [
                158.52,
                1709874000
            ],
            [
                164.53,
                1710129600
            ],
            [
                163.75,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8665,
        "drug_name": "WAINUA (eplontersen)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Hereditary ATTR Amyloidosis (hATTR)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-12-22",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/AZN\/news\/176762",
        "note": "Approved December 22, 2023.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": [
            {
                "label": "Orphan Drug Designation (ODD)",
                "abbreviation": "ODD",
                "description": "Orphan Drug Designation (ODD)",
                "description_html": "<p>Orphan Drug Designation (ODD)<\/p>\n"
            }
        ]
    }
]